Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 2/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPA3 | P15088 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5685248 | 0.82 | EEF2K (0.50) | EEF2KFFAR1MEN1KMT2ACNR2 | |
| SCHEMBL27728236 | 0.82 | CPA3 (0.45) | EEF2KMEN1KMT2ACNR2HIF1A | |
| SCHEMBL31581805 | 0.82 | EEF2K (0.39) | EEF2KFFAR1MEN1KMT2ACTSA | |
| SCHEMBL26455960 | 0.81 | MEN1 (0.48) | EEF2KMEN1KMT2ACNR2HIF1A | |
| SCHEMBL8770868 | 0.79 | CES2 (0.49) | EEF2KFFAR1MEN1KMT2ACNR2 | |
| SCHEMBL559436 | 0.79 | TSHR (0.62) | FFAR1CPA1CPB1CPA3CPB2 | |
| SCHEMBL6841260 | 0.79 | FFAR1 (0.49) | FFAR1CTSA | |
| SCHEMBL1645769 | 0.78 | FFAR1 (0.47) | FFAR1CPA1CPB1CPA3CPB2 | |
| SCHEMBL2457680 | 0.78 | EEF2K (0.47) | EEF2KMEN1KMT2ACNR2CES2 | |
| SCHEMBL1646855 | 0.78 | FFAR1 (0.47) | FFAR1CPA1CPB1CPA3CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531615-A | Indenyl compound, pharmaceutical composition and medical application thereof | ADT制药有限责任公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107466232-A | The method for treating or preventing the disease of RAS mediations | ADT制药有限责任公司 | 2017-12-12 | — | — | CN | disclosed |
| EP-3233794-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3233071-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2341140-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016100546-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100542-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| EP-1021402-B1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | UNIV DUKE (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005068411-A1 | PROCESS FOR THE PREPARATION OF 6-FLUORO-2-METHYL-1-INDANONE | ZAMBON GROUP S.P.A. (IT) | 2005-07-28 | — | — | WO | disclosed |
| EP-1146866-A4 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI PHARM INC (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1146866-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1082299-A1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS MEDICAMENTS | THE PROCTER & GAMBLE COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6107338-A | BONE DISORDERS; GLAUCOMA | THE PROCTER & GAMBLE COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000044372-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | CELL PATHWAYS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021402-A1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999050241-A1 | C11 OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS MEDICAMENTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999012896-A1 | AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO PROSTAGLANDINS USEFUL AS FP AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
| EP-0723442-A4 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0723442-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996003987-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-02-15 | — | — | WO | disclosed |